8-K: Vistagen Appoints Nick Tressler as New CFO

Vistagen Therapeutics strengthens its leadership team with the appointment of Nick Tressler as Chief Financial Officer, effective December 1, 2025.

Summary

• Vistagen Therapeutics, Inc. (Nasdaq: VTGN) announced the appointment of Nick B. Tressler as its new Chief Financial Officer (CFO) and Treasurer, effective December 1, 2025.
• Mr. Tressler will also serve as the company's principal financial and accounting officer, taking over from Shawn K. Singh, who previously held the interim role.
• Mr. Tressler, age 52, brings over 20 years of financial leadership experience in the life sciences industry, including previous CFO roles at DYNEX Technologies, American Gene Technologies International, and Senseonics Holdings, Inc.
• His compensation package includes a starting annual base salary of $450,000, a $50,000 signing bonus, and eligibility for an annual discretionary cash bonus with an initial target of 45% of his base salary.
• Mr. Tressler was granted stock options to purchase 150,000 shares of common stock, with an exercise price of $4.43 per share, vesting 25% on the one-year anniversary of the effective date and monthly thereafter over 36 months.
• An Indemnification Agreement was entered into between the company and Mr. Tressler, effective December 1, 2025, to indemnify him to the fullest extent permitted by Nevada law and advance certain expenses.

Sentiment

Score: 8

Explanation: The filing conveys a strong positive sentiment, primarily due to the appointment of a highly experienced Chief Financial Officer. The language used by management expresses enthusiasm for the new hire's strategic contributions and the company's future growth prospects, including 'major clinical milestones' and 'long-term value creation'.

Positives

• The appointment of Nick Tressler, an experienced financial leader with over two decades in the life sciences industry, is expected to strengthen Vistagen's executive team.
• Mr. Tressler's background includes guiding companies through pivotal growth and transformation, which aligns with Vistagen's stated 'next phase' and 'major clinical milestones on the horizon'.
• Management expressed excitement about Mr. Tressler's financial and strategic acumen and operational experience, anticipating a positive impact on the company's strategic priorities and long-term value creation for shareholders.
• The company highlights a 'deep pipeline' and a 'mission-driven team committed to delivering innovative therapies for patients who need better treatment options'.

Risks

• Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected or implied.
• Risks are more fully discussed in Vistagen's Annual Report on Form 10-K for the fiscal year ended March 31, 2025, and Quarterly Report on Form 10-Q for the period ended September 30, 2025.

Future Outlook

Vistagen is a late clinical-stage biopharmaceutical company focused on pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. The company anticipates major clinical milestones on the horizon and aims to advance strategic priorities with financial strategies focused on long-term value creation for shareholders, developing transformative treatment options for social anxiety disorder, major depressive disorder, and vasomotor symptoms.

Management Comments

• "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase." Shawn Singh, President and Chief Executive Officer of Vistagen.
• "I look forward to his contributions to our leadership team and the positive impact he will have throughout our company as we continue building momentum and delivering on our vision." Shawn Singh.
• "It's an honor to join Vistagen at such a pivotal moment in the company's evolution, with major clinical milestones on the horizon, a deep pipeline, and a mission-driven team committed to delivering innovative therapies for patients who need better treatment options." Nick Tressler, Chief Financial Officer of Vistagen.
• "I look forward to working with our team to advance our strategic priorities with financial strategies focused on long-term value creation for our shareholders." Nick Tressler.

Industry Context

Vistagen operates in the biopharmaceutical industry, specifically focusing on neuroscience and developing a new class of intranasal product candidates called pherines. This sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The appointment of an experienced CFO with a background in life sciences companies, including those acquired by larger pharmaceutical entities, suggests a focus on financial strategy to support clinical development and potential commercialization or strategic transactions in a competitive and capital-intensive industry.

Management Changes

Corporate Governance

Related Party Transactions

• None disclosed, as Mr. Tressler is not a participant in any related party transaction required to be reported pursuant to Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Potential positive impact through strengthened financial leadership, strategic acumen, and focus on long-term value creation.
• Employees: The appointment of a new CFO can signal stability and strategic direction, potentially boosting morale and confidence in leadership.
• Customers/Patients: Indirect positive impact through a more robust financial strategy supporting the development and commercialization of innovative therapies for underserved medical conditions.

Next Steps

• Mr. Tressler will work with the Vistagen team to advance strategic priorities with financial strategies focused on long-term value creation for shareholders.
• Vistagen will continue to pursue its mission of developing transformative treatment options for indications such as social anxiety disorder, major depressive disorder, and vasomotor symptoms.

Key Dates

Keywords

CFO appointment, Chief Financial Officer, Vistagen Therapeutics, VTGN, biopharmaceutical, life sciences, executive compensation, corporate governance, stock options, indemnification agreement, Nasdaq